OncoTherapy Science, Inc. (TYO:4564)
23.00
0.00 (0.00%)
Sep 16, 2026, 3:09 PM JST
OncoTherapy Science Revenue
OncoTherapy Science had revenue of 170.00M JPY in the quarter ending June 30, 2026, a decrease of -15.42%. This brings the company's revenue in the last twelve months to 777.00M, down -8.70% year-over-year. In the fiscal year ending March 31, 2026, OncoTherapy Science had annual revenue of 808.00M with 7.73% growth.
Revenue (ttm)
777.00M
Revenue Growth
-8.70%
P/S Ratio
12.08
Revenue / Employee
16.89M
Employees
46
Market Cap
9.39B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 808.00M | 58.00M | 7.73% |
| Mar 31, 2025 | 750.00M | 140.00M | 22.95% |
| Mar 31, 2024 | 610.00M | -524.00M | -46.21% |
| Mar 31, 2023 | 1.13B | -19.00M | -1.65% |
| Mar 31, 2022 | 1.15B | 821.00M | 247.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.14B |
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.08B |
| Carna Biosciences | 729.00M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |
| Kubota Pharmaceutical Holdings | 16.00M |
| BrightPath Biotherapeutics | 84.00K |